Drugs that make more money sought
By Christopher Rowland, Globe Staff, 3/13/2004
America's drug industry, including anti-infection pioneers Eli Lilly & Co. and Wyeth, is abandoning research into antibiotics in favor of more lucrative drugs at a time when patients need new versions to fight drug-resistant bacteria.
New antibiotic research has taken a back seat because companies are chasing larger drug markets that promise bigger profits such as pills for depression, heartburn, and erectile dysfunction. The shift to treat chronic ailments and "lifestyle" complaints is of growing concern among infectious disease doctors who say market conditions are steering manufacturers away from areas of critical medical need.
http://www.boston.com/news/nation/articles/2004/03/13/firms_abandoning_antibiotics_research/
By Christopher Rowland, Globe Staff, 3/13/2004
America's drug industry, including anti-infection pioneers Eli Lilly & Co. and Wyeth, is abandoning research into antibiotics in favor of more lucrative drugs at a time when patients need new versions to fight drug-resistant bacteria.
New antibiotic research has taken a back seat because companies are chasing larger drug markets that promise bigger profits such as pills for depression, heartburn, and erectile dysfunction. The shift to treat chronic ailments and "lifestyle" complaints is of growing concern among infectious disease doctors who say market conditions are steering manufacturers away from areas of critical medical need.
http://www.boston.com/news/nation/articles/2004/03/13/firms_abandoning_antibiotics_research/